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Summary 
The vast majority of new human HLA class I alleles are formed by conversions between exist- 
ing alleles of the same locus. A notable exception to this rule is HLA-B*4601 formed by re- 
placement  of residues  66-76  of the  otl  helix  of B'1501  by  the  homologous  segment  of 
Cw*0102.  This inter-locus recombination, which brings  together characteristic elements of 
HLA-B and HLA-C structure, is shown here to influence function dramatically. Naturally pro- 
cessed peptides bound by B'4601  are distinct from those of its parental allotypes B'1501  and 
Cw*0102 and dominated by three high abundance peptides. Such increased peptide selectivity 
by B'4601  is unique among HLA-A,B,C allotypes.  For other aspects of function, presence of 
the small segment of HLA-C-derived sequence in an otherwise HLA-B framework converts 
B'4601  to  an  HLA-C-like molecule. Alloreactive cytotoxic T  lymphocytes (CTL),  natural 
killer (NK) cells, and cellular glycosidases all recognize B'4601 as though it were an HLA-C al- 
lotype. These unusual properties are those of an allotype which has frequencies as high as 20% 
in south east Asian populations and is associated  with predisposition to autoimmune diseases 
and nasopharyngeal carcinoma. 
I 
n human populations, divergence of major histocompati- 
bility complex class I loci has been facilitated by the rarity 
of inter-locus recombination (1). Thus HLA-B and -C which 
were formed by duplication of a common ancestor (1) now 
have distinctive polymorphism (2) and levels of expression 
(3)  suggestive of functional specialization.  In this context, 
B'4601  is an exceptional allele  in which HLA-B-specific 
and HLA-C-specific sequences have been  combined  (4). 
B'4601  is the product of an inter-locus recombination in- 
volving B'1501  and Cw*0102 where an HLA-C-derived 
sequence encoding residues  66-76 of the or1 helix is placed 
within  a  typically  HLA-B  framework.  In  consequence, 
B'4601  differs from B'1501 by seven amino acid substitu- 
tions; Lys from lie at 66, Tyr from Ser at 67, Arg from Thr 
at 69,  Gln from Asn at 70, Ala from Thr at 71, Asp from 
Tyr at 74,  and Val from Glu at 76.  Residues within the 
segment 66-76  contribute both to formation of the pep- 
tide-binding site  and the  membrane-distal surface  of the 
class I glycoprotein with which CTL and NK cell receptors 
interact. Residue differences between B'4601  and B'1501 
are therefore likely to influence class I function. 
The  B'4601  allotype  is  common  in  south  east  Asian 
populations where it is found at frequencies up to 20% (5), 
and is known for its association with susceptibility to na- 
sopharyngeal carcinoma (6-7) and the autoimmune diseases 
myasthenia gravis  (8)  and Graves'  disease  (9-12).  Despite 
apparent association with predisposition to certain diseases, 
B46 haplotypes surpass the frequency of the parental B15- 
Cwl  haplotype by more than fourfold (13) in south east 
Asia. Ascendance of B'4601  suggests the residue substitu- 
tions introduced by the inter-locus recombination produce 
functional changes that confer selective advantage. To de- 
termine how the conversion event that created B'4601  af- 
fects the function of the class I glycoprotein, properties of 
B'4601  and the  parental allotypes B'1501  and Cw*0102 
were compared. 
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Cell Lines.  Transfected versions of the HLA-A,B,C negative 
EBV-transformed B  lymphoblastoid cell line 721.221  expressing 
B'4601, B'1501, or Cw*0102 were generated as described previ- 
ously (14).  Cell surface expression of the transfected class I alleles 
was monitored on a regular basis by immunofluorescent staining 
and flow cytometric analysis as described (14). 
Purification and Analysis  of Naturally  Processed Peptides Bound  by 
HLA Class I Allotypes.  Class I glycoprotein was purified and bound 
peptides isolated and characterized essentially as described in (15). 
Class I glycoproteins were purified from detergent lysates  of 1 ￿ 
101~ cells  using the  HLA  class  I-specific  monoclonal antibody 
W6/32  (16).  Separate  batches  of antibody were  used  to  purify 
each allotype. Purity of the class I protein was assessed by SDS- 
PAGE and Coomassie blue staining, and yields quantified by den- 
sitometry based on comparisons to known amounts of a protein 
standard. Bound peptides were released by denaturation of class I 
glycoprotein with 10% acetic acid and isolated using a 3-kD molec- 
ular mass cut off ultra filtration unit. Peptides were separated by 
HPLC using a reversed-phase Beckman Ultrasphere C-18 2.0 ￿ 
250-mm column (Beckman Instruments Inc., Fullerton, CA) us- 
ing the gradient described in (15).  Peptide sequence analysis was 
performed using an automated protein sequencer (model 476A; 
Perkin Elmer Applied Biosystems Division, Foster City, CA) op- 
erated in gas-phase mode. Cys was not derivitized and therefore 
not detectable.  Sequence analysis of the pool of peptides bound 
by each allotype was performed using 30% of each HPLC fraction 
collected  between  15  through  65  min.  Residue  preferences  at 
each  position are  grouped into the  following categories:  domi- 
nant; (yield of a single amino acid increases several fold over the 
previous cycle); strong (amino acids with more than a twofold in- 
crease  over the  previous cycle); weak  (amino acids with an in- 
crease of between 1.5- and 2-fold over the previous cycle). Resi- 
dues at each position are listed in order of decreasing size  of the 
picomole increase relative to the previous cycle. HPLC fractions 
containing  well resolved peaks from the absorbance trace at 214 nm 
were selected for sequence analysis of individual peptides. Yields 
of individual peptide sequences are based on initial sequence lev- 
els.  Sequences assignments for all peptides isolated from B'4601 
were confirmed by mass measurement and MS/MS experiments. 
Mass  spectra  were  acquired  using a  PE  SCIEX API  300  triple 
quadropole mass spectrometer (Perkin Elmer Applied Biosystems 
Division, Foster City, CA) with an ionspray source operating in 
the positive ion mode. Proteins from which the peptides could be 
derived were identified by searching the GenBank database. 
Molecular Modeling.  Residues 1-180 ofB'4601 were modeled 
using self-consistent ensemble optimization (SCEO)  (17,18),  via 
the  program LOOK  (Molecular Applications Group,  Palo Alto 
CA).  A  multiple structural alignment of class I  crystal structures 
B'2705, Aw68, A*0201 and H-2D  b was performed, and B'4601 
modeled  primarily from  B'2705  (for  residues  38-65  and  103- 
151), but also Aw68 (1-37, 68-76, 152-180), A*0201 (66-67, 82- 
102) and H-2D  b (77-81). Residues modeled ab initio in the pep- 
tide binding site included 7, 9, 45, 63, 66, 67, 69, 70, 97, 99, 114, 
116,  152,  and  163.  To  model  the  proteasome  component C8 
peptide bound to B'4601, the coordinates of A'0201 complexed 
with a decamer peptide from hepatitis B  (19) were superimposed 
on the B'4601  nmdel, and the proteasome component C8 resi- 
dues  150-159  (YMIDPSGVSY)  modeled on the  peptide  back- 
bone using SCEO. 
Preparation of CTL Lines and NK Cell Clones, and Cell-mediated 
CytotoxidtyAssays.  Allogenic  CTL  lines  were  generated  by 
coculture  of human  PBL  from  healthy  donors  with  irradiated 
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(10,000  rads)  721.221  transfected  cells  expressing  13"4601. 
B'1501,  or Cw*0102  (ratio of 5:1).  CTL lines were  cultured in 
IMDM medium supplemented with 10% FCS, 2% human serum, 
2 mM L-GIn, 100 U/ml penicillin, 100 b~g/ml streptomycin and 
maintained at  37~  in a  humidified atmosphere  containing 5% 
CO  2.  Two  weeks  after  cultures  were  established,  cells  were 
stained with Simultest CD3/CD8  (Becton Dickinson and Com- 
pany, Mountain View, CA) and cells  expressing CD3 and CD8 
were  collected using a  FACStarPLUS  |  flow cytometer  (Becton 
Dickinson).  CTL  lines were  restinmlated every  7  d  and,  after 
sorting,  were  maintained in medium additionally supplemented 
with  10%  Lymphocult-T  (BioTest).  Allogenic NK  cell  clones 
(CD3-, CD56+) were prepared as described (14). All CTL lines 
and NK cell clones were tested for expression of appropriate cell 
surface markers by imnmnofluorescent staining and flow cytome- 
try.  Cytolytic activity was  determined in a  standard  4  h  chro- 
mium release assay and results expressed as percent specific lysis 
calculated as follows: percent specific lysis =  (experimental cpm - 
spontaneous cpm)/(total cpm -  spontaneous cpm) X  100. Assays 
were performed in duplicate or triplicate and repeated 2-5 times. 
Release and Analysis  qf Oligosaccharides.from HLA  Class I  Glyco- 
proteins.  Oligosaccharides were  released from  purified desalted 
class I glycoprotein using the GlycoPrep 1000, labeled at the reduc- 
ing terminus using the Signal Labeling method, and de-sialylated 
by digestion with neuraminidase as described (20).  Fractionation 
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Peptide Position 
1  2  3  4  5  6  7  6 
Dominant 
Strong 
Weak 
MKDPSE 
REI 
NV 
II  GAG 
P 
F 
V  Y 
A  F 
B'4601  endogenously-bound  peptides (from 350pg  B'4601) 
Fraction  Sequence  Yield (pmol)  Homologous protein 
14  '~'rxDGSSTY  46  No match  found 
16  szR~"v1~.Y  8  No match found 
20  ~o~.E-r,~y  34  Human HSCT0 t  HSP70 {t26-134) 
36  'ZM]:DPSG'VSY  166  Human proteasome subunlt C8 (150-159) 
40  ~rvzP'r~/H,~  9  No match found 
41  FAFV'II:~TY  1 0  Human cyclin  B  (269-277) 
B'1501  peptide pool 
1 
Dominant 
Strong 
Weak 
Peptide Position 
2  3  4  5  6  7  8  9 
Q  K  P  I  Y 
L  F  E  F 
M  R  D 
N 
Y 
P 
H  G  M 
B'1501  endogenously-bound peptides (from  50Ol~g B'1501) 
Fraction  Sequence  Yield (pmol)  Homologous  protein 
1 O  SQFC-GGSQY  4 3  NO match found 
1 9  GQRKGAGSVF  63  Human ribosome protein L8 (7-16) 
Cw'0102  peptide pool 
Peptide Position 
1  2  3  4  5  6  7  8  9  Fraction  Sequence 
Dominant  23  ZA~i'GXSL  1 03 
Strong  A  P  E  R  V  L  29  ZT~rG~PL  26 
L  V  H  I  34  AAPA~SP,  AL  46 
Y  K  44  FAPIrNKPSL  64 
T  51  HLpETKFSEL  40 
S  65  NAPWAVTSL  28 
W  70  VAPWNSLSL  70 
Weak  Q  A  G  H  F  71  NXPERI  ITL  66 
L 
N 
R 
F 
Cw*Ol02 endogenously-bound peptides (from  750p.g Cw*0102) 
Yield (pmol) Homologous  protein 
No match found 
Human granulin  (162-170) 
Human HSP27 (69-81) 
No match found 
No match found 
Human butynJl cholinesteraso (228-236) 
Human tissue inhibitor  o~ metalloprotcinase  (66-69) 
If X = Cys,  human nucleic  acid-binding  protein (53-61) 
Figure 1.  Analysis  of the naturally processed  peptides bound by B'4601, B'1501 and Cw*0102. Bound  peptides were isolated  from 350 }xg B'4601, 500 
~tg B'1501, and 700 Ixg Cw*0102, respectively  and separated by reversed  phase HPLC (a, c, and e). Peptide  sequences  were determined  by Edman deg- 
radation and mass spectrometry  (b, d, and/). 
by gel filtration was performed using the GlycoMap 1000. All in- 
strmnentation  and  reagents were  from  Oxford  GlycoSystems 
(Abingdon, U.K.). 
Results and Discussion 
To  determine  how  the  inter-locus  recombination be- 
tween B'1501 and Cw*0102 that created B'4601 modified 
peptide binding specificity we  characterized the  naturally 
processed  peptides  bound  by  these  allotypes.  Reversed 
phase  HPLC  of the  peptide  pools  showed  B'1501  and 
Cw*0102 (Fig.  1, c and e) had typically "humped" profiles 
indicative of heterogeneous peptides (15,  21) whereas pep- 
tides eluted from B'4601 gave a flatter profile having a few 
dominant peaks (Fig.  1 a) which contained high abundance 
peptides  (Fig.  1 b).  Most abundant was  a peptide derived 
from proteasome subunit C8, and its sequence dominated 
when the pool ofpeptides eluted from B'4601 was sequenced 
(Fig. 1 b). Two of the three most abundant peptides derive 
from constitutively expressed proteins (22, 23) consequently 
the peptides displayed by B'4601 in most cell types may be 
dominated by a few peptides. 
In marked contrast to B'4601, the peptides isolated from 
the parental  allotypes, B'1501  and  Cw*0102,  comprise  a 
complex  mixture  containing  no  predominating  peptides 
(Fig.  1, c-f). Pool sequencing revealed residue preferences 
at two positions defining their peptide-binding motifs (Fig. 1, 
d and f). None of six individual B*4601-binding peptides 
(Fig.  1 b) possess either the B'1501  (Gin at position 2, Phe 
or Tyr at position 9)  or the Cw*0102  (Pro at 3, Leu at 9) 
motif.  Neither were  the  B*4601-binding  peptides  found 
amongst  the  peptides  eluted  from B'1501  or  Cw*0102. 
Preferential binding of a subset of peptides by B'4601 is al- 
most certainly a result of its unique structure and not other 
factors affecting antigen presentation as the peptides we iso- 
lated from B'4601, B'1501  and Cw*0102 derive from the 
identical cellular background. 
Modeling suggests  three features of the B'4601  peptide 
binding site combine to augment peptide selectivity (Fig. 2). 
The  HLA-C-derived  sequence  introduces  a  basic  patch 
(Arg 62, Lys 66, and Arg 69) into the peptide-binding site 
which may account for selective binding of peptides with 
acidic  side  chains  at  position  4;  a  feature  shared  by  the 
dominant peptides bound by B'4601  (Fig.  1 b). Examina- 
tion of the subsites  within the peptide-binding site  desig- 
nated pockets A  through F  suggests  additional constraints 
on peptide selectivity by B'4601 may reflect a truncated B 
pocket due to Tyr 67 and Glu 63 which likely restricts res- 
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tide binding site.  (Top  left)  Ribbon diagram of the 
cd and or2 domains ofB'4601 showing the HLA-C- 
derived sequence (red) present at residues 66-76  of 
the  cq  helix.  (Top  r(ght)  Molecular  surface  of 
B'4601  showing the basic groups Arg 62,  Lys 66, 
Arg  69  (blue)  immediately adjacent  to  the  Asp  at 
posmon  4  of  the  proteasome  component  CS- 
derived peptide  (peptide  is shown in bonds).  (Bot- 
tom  left)  Cut-away  view  showing  the  B  pocket 
truncated by Tyr 67  (pink)  creating a  shallow de- 
pression for accommodating the peptide position 2 
Met side chain  (purple,  ball  and  stick).  (Bottom  right) 
Cut-away view showing the deep F pocket due to 
Ser 116  (olive) accomanodating the peptide COOH- 
terminal Tyr side chain (red,  ball and stick). 
A  Anti B'4601 CTL Line  Anti Cw*0102 CTL Line 
untransfected  B'4601  B'1501  Cw*0102  untransfected  B'4601  B*1501  Cw*0102 
721.221  721.221 
Anti B'1501 CTL Line 
untransfected  B'4601  B'1501  Cw*0102 
721.221 
B  Group I HLA-C-Specific  NK Cell Clone 
100  100 
/  / 
~6o i  -~6o~4~ 
"..~ 
Y~  40  "~ 
°-~  20  o  20 
o  i  r  ~  i  i  i  0 
untransfected  Cw'1503  Cw*0102  B'4601  B'1501 
721.221 
Group II HLA-C-Specific  NK Cell Clone 
tlntral~$fected  Cw'1503  Cw*0102  B'4601  B'1501 
721.221 
Figure 3.  Alloreactive CTL and NK ceils recognize B'4601 as HLA-C-like. Results shown in A are percent specific lysis ofuntransfected 721.221 cells 
and 721.221 cells transfected with B'4601, B'1501 or Cw*0102 by CTL lines raised from one donor against B'4601  (left),  Cw*0102  (middle)  or B'1501 
(righO. Assays shown were performed at an effector to target ratio of 2.5:1 for anti B'4601 and anti B'1501 CTL lines and 5:1  for the anti Cw*0102 CTL 
line. Cross reactive recognition ofB'4601  and Cw*0102 but not B'1501  was observed for CTL lines raised fi'om all three donors tested. Results shown 
Figure 3  B are percent specific lysis of untransfected 721.221  cells and 721.221  cells transfected with B'4601, B* 1501, Cw*0102  ~roup  1) or Cw* 1503 
(group  I1) by a group l~specific NK cell clone (/eft) and a group II-specific clone (right).  Expression ofB'4601  or Cw*0102 but not B*1501  protects cells 
from lysis by group I HLA-C-specific NK cells. B'4601 inhibited lysis by all group I but not group 1I HLA-C-specific NK cell clones isolated and tested 
from three healthy donors (total 31  clones). 
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Figure  4.  Gel filtration chromatograms of the desialylated N-linked 
oligosaccharide pools released from  B'4601,  Cw*0102 and  B'1501. 
B'4601  carries the  same four  oligosaccharides (A,  B,  C,  and  D)  as 
Cw*0102 whilst B'1501 has the more restricted set comprising oligosac- 
charides A and B only. Numerical superscripts in each chromatogram 
represent the elution position in glucose units of unlabeled coapplied lin- 
ear glucose oligomers (obtained as a partial hydrolysate  ofdextran). 
idues permissible  at peptide position 2,  and a large deep F 
pocket,  held  in  common with  the  B'1501  parent,  which 
selects  for peptides  with  carboxyl-terminal  aromatic  resi- 
dues. 
Despite sharing greatest homology to B*1501, the HLA-C- 
derived sequence at residues  66-76 dominates  the interac- 
tion of B'4601  with both alloreactive  CTL and NK cells. 
Most alloreactive CTL lines were found to exhibit cross re- 
active recognition of B'4601  and Cw*0102,  but no cross- 
reactivity between B*1501  and B'4601 was observed (Fig. 
3  a).  Class  I  receptors  of NK  cells  also  view  B'4601  as 
HLA-C-like.  HLA-C  allotypes  can  be  divided  into  two 
groups based upon their capacity to inhibit lysis by distinct 
subsets  of allogenic  NK  cells  (24,  25).  B'4601  inhibited 
NK cell clones having specificity for group I HLA-C allo- 
types such as Cw*0102, but B'1501 was not inhibitory for 
NK cells of either specificity (Fig. 3 b). 
The HLA-C-derived sequence also exerts an overriding 
influence on the N-linked glycosylation ofB'4601. HLA-B 
and  C  aUotypes have  distinctive patterns  of N-linked  gly- 
cosylation at position 86 (20), close to the HLA-C-like se- 
quence possessed by B'4601. Structural analysis of the gly- 
cans  of B'4601  showed  the  typically  HLA-C  pattern  of 
four oligosaccharides and not the  more  restricted  HLA-B 
pattern  of two  oligosaccharides  (Fig.  4).  Substitutions  at 
residues  66-76  therefore  make  B'4601  an  HLA-C-like 
substrate for glycosyl transferases. 
The inter-locus recombination which generated B'4601 
created  a  molecule with  novel peptide-binding  properties 
and  imposed  features  characteristic  of HLA-C  onto  an 
HLA-B  allotype.  These  results  demonstrate  the  radical 
changes in class  I function that can be effected by a single 
gene  conversion.  That  B46  haplotypes  are  common  in 
south east Asia (5) and surpass the frequency of the parental 
B15-Cwl haplotype (13) suggests the unusual properties of 
B'4601  confer selective  advantage.  Indeed  the  functional 
competence  of B'4601  is  indicated  by the  discovery of a 
healthy individual  who is  homozygous for the  B46-Cw1 
haplotype and lacks expression of HLA-A (26). In contrast, 
the association of B46 with predisposition  to autoimmune 
disease (8-12) and nasopharyngeal carcinoma (6-7), a prev- 
alent cancer in southeast Asia involving Epstein-Barr virus 
(27),  suggest  negative  effects  may also  be  associated  with 
the  unusual  properties  of B'4601.  Presentation  of high 
amounts of a few peptides by B'4601 may impose biases on 
the  T  cell  repertoire  (as  reported  for  patients  possessing 
B'4601 with nasopharyngeal carcinoma [28]) that strengthen 
or weaken T  cell responses to individual  antigens  with an 
intensity not seen with less discriminating allotypes. 
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